Journal Mobile Options
Table of Contents
Vol. 5, No. 3-4, 2008
Issue release date: March 2008
Section title: Aging
Free Access
Neurodegenerative Dis 2008;5:261–263

Assessing Change in Cognitive Function in Dementia: The Relative Utilities of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale and the Cognitive Drug Research System

Wesnes K.A.
Cognitive Drug Research Ltd., Goring-on-Thames, and Human Cognitive Neuroscience Unit, Northumbria University, Newcastle upon Tyne, UK; Brain Sciences Institute, Swinburne University, Hawthorn, Vic., Australia
email Corresponding Author

Prof. Keith A Wesnes, PhD

Cognitive Drug Research Ltd., CDR House

Gatehampton Road

Goring-on-Thames RG8 0EN (UK)

Tel. + 44 1491 878 700, Fax +44 1491 878 701, E-Mail


  1. Wesnes K, Harrison J: The evaluation of cognitive function in the dementias: methodological and regulatory considerations. Dialogues Clin Neurosci 2003;5:77–88.
  2. Ferris S, Lucca U, Mohs R, Dubois B, Wesnes K, Erzigkeit H, Geldmacher D, Bodick N: Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11(suppl 3):34–38.
    External Resources
  3. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK: The Cognitive Drug Research computerised assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991;6:95–102.
    External Resources
  4. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R: Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183–192.
  5. Wesnes KA, Harrison J, Edgar C, Pincock C: The sensitivity and reliability of the Cognitive Drug Research computerised cognitive assessment system to disease progression and treatment response in Alzheimer’s disease. Int Psychogeriatr 2005;17(suppl 2):154.
  6. Bronnick K, Ehrt U, Emre M, De Deyn PP, Wesnes K, Tekin S, Aarsland D: Attentional deficits affect activities of daily living in dementia associated with PD. J Neurol Neurosurg Psychiatry 2006;77:1136–1142.
  7. Mohr E, Walker D, Randolph C, Sampson M, Mendis T: The utility of clinical trial batteries in the measurement of Alzheimer’s and Huntington’s dementia. Int Psychogeriatr 1996;8:397–411.
  8. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O’Brien JT, Ballard CG: Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease and vascular dementia. Neurology 2000;54:1616–1625.
  9. Zaffalon M, Wesnes K, Petrini O: Reliable diagnosis of dementia by the naïve credal classifier inferred from incomplete cognitive data. Artif Intell Med 2003;29:61–79.
  10. Wesnes K: The role of attention deficits in the cognitive pathology of dementia. Alzheimer Insights 2001;7:1–4.
  11. Vellas B, Cunha L, Gertz HJ, De Deyn PP, Wesnes K, Hammond G, Schwalen S: Early onset effects of galantamine treatment on attention in patients with Alzheimer’s disease. Curr Med Res Opin 2005;21:1423–1429.
  12. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–2036.
  13. Emre M, Aarsland D, Albanese A, et al: Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351:2509–2518.
  14. Wesnes KA, McKeith IG, Edgar C, Ferrara R, Emre M, Lane R: Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654–1656.
  15. Rowan E, McKeith IG, Saxby BK, Newby, Daniel S, Sanders J, Wesnes KA: Effects of donepezil on central processing speed and attentional measures in Parkinson’s disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2007;23:161–167.
  16. Cummings JL: Commentary, cholinesterase inhibitors: expanding applications. Lancet 2000;356:2024–2036.
  17. Press DZ: Parkinson’s disease dementia – A first step? N Engl J Med 2004;351:2547–2549.